Trending

Sandoz

FDA clears Pear/Sandoz app for opioid use disorder

FDA clears Pear/Sandoz app for opioid use disorder

A second mobile app developed by Pear Therapeutics to help opioid use disorder patients who have a more

X

FDA clears Pear/Sandoz app for opioid use disorder

https://pharmaphorum.com/news/fda-clears-pear-sandoz-app-for-opioid-use-disorder/

NHS saving £300m with Humira biosimilar deal

NHS saving £300m with Humira biosimilar deal

The NHS is to save £300 million after striking deals with several manufacturers of low cost biosimilars of

X

NHS saving £300m with Humira biosimilar deal

https://pharmaphorum.com/news/nhs-saving-300m-with-humira-biosimilar-deal/

Sandoz axes filing of US Rituxan biosimilar

Sandoz axes filing of US Rituxan biosimilar

Sandoz has abandoned plans to get a cheaper biosimilar of Swiss rival Roche’s cancer drug Rituxan (rituximab) approved

X

Sandoz axes filing of US Rituxan biosimilar

https://pharmaphorum.com/news/sandoz-axes-filing-of-us-rituxan-biosimilar/

Billions up for grabs as EU patent on AbbVie’s Humira expires

Billions up for grabs as EU patent on AbbVie’s Humira expires

The patent for Humira, the world’s bestselling drug, expires in Europe today – opening the door for a

X

Billions up for grabs as EU patent on AbbVie’s Humira expires

https://pharmaphorum.com/news/billions-up-for-grabs-as-eu-patent-abbvies-humira-expires/

Sandoz free to launch Humira biosimilar following AbbVie deal

Sandoz free to launch Humira biosimilar following AbbVie deal

Novartis’ generics and biosimilars arm, Sandoz, has confirmed it is to launch its biosimilar of AbbVie’s Humira (adalimumab)

X

Sandoz free to launch Humira biosimilar following AbbVie deal

https://pharmaphorum.com/news/sandoz-free-to-launch-humira-biosimilar-following-abbvie-deal/

Digital health round-up – government and Sandoz recognise trailblazing projects

Digital health round-up – government and Sandoz recognise trailblazing projects

Richard Staines presents his weekly round-up of the latest digital health headlines

X

Digital health round-up – government and Sandoz recognise trailblazing projects

https://pharmaphorum.com/views-and-analysis/government-digital-health-catalyst/

Sandoz encourages digital health innovation in second competition

Sandoz encourages digital health innovation in second competition

Sandoz has announced a second competition inviting entrepreneurs and innovators in digital health to submit ideas that could

X

Sandoz encourages digital health innovation in second competition

https://pharmaphorum.com/news/sandoz-encourages-digital-health-innovation-in-second-competition/

Novartis sells parts of Sandoz for $1bn

Novartis sells parts of Sandoz for $1bn

After disappointing sales, Novartis trades in the Sandoz US dermatology business and generic oral solids portfolio to Aurobindo

X

Novartis sells parts of Sandoz for $1bn

https://pharmaphorum.com/news/novartis-sells-sandoz-parts/

Fourth Humira biosimilar set for EU approval

Fourth Humira biosimilar set for EU approval

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s

X

Fourth Humira biosimilar set for EU approval

https://pharmaphorum.com/news/humira-biosimilar-eu-sandoz-chmp/

1 2 3 4

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com